Navigation Links
Federal nanotech risk research plan still comes up short

WASHINGTON, DC An improved but still flawed government-wide plan for nanotechnology risk research is the result of a broken system. Federally-funded studies essential to managing possible risks from this cutting-edge technology should be guided by a top-down strategy tied to projected commercialization, expected human and environmental exposures, and the regulatory decision-making process.

The National Nanotechnology Initiatives (NNI) Nanotechnology Environmental and Health Implications (NEHI) Working Group recently released its strategy for nanotechnology environmental, health and safety research. The strategy outlines an improved focus on risk research for more than 20 federal agencies, including the Environmental Protection Agency (EPA), the Food & Drug Administration (FDA) and the Consumer Product Safety Commission (CPSC). Earlier drafts of the strategy received widespread criticism from industry officials, policy experts and congressional lawmakers for being merely a list of general nanotechnology risk research categories. The new strategy makes substantial strides towards identifying prioritized research needs and assigning lead agencies to address these needs.

Also just released, the new EPA Office of Research & Development nanotechnology risk research plan appears to be in lock step with the NEHI strategy. The EPA plan includes important studies on risk assessment methods and life-cycle analysis to determine the eventual fate of nanomaterials.

But major hurdles still stand in the way of the public, industry and government obtaining a better understanding of the risks posed by nanomaterials and how to limit those risks. Necessary resources for nanotechnology risk research are few and far between in relevant oversight agencies such as the EPA, FDA and CPSC. In addition, a limited investment by the NNI on occupational exposure research can only increase dangers to those most susceptible workers.

The truth is that while the NEHI made significant strides in this latest effort to present an improved nanotechnology risk research strategy, only about five of the more than 240 identified risk research projects focus on exposure assessment which directly affects workers. These are the people who are on the front line and most likely to be exposed to potentially hazardous nanomaterials, says David Rejeski, the director of the Project on Emerging Nanotechnologies (PEN).

The document also fails to employ a top-down, strategic approach aimed at directing funds and research at the places where theres likely to be the most risk, according to Rejeski. The NEHI structure and plan are still broken. The plan is a collection of individual agency research programs and not a strategic approach appropriate to a technology projected to be incorporated into $2.6 trillion worth of products by 2014.

An earlier analysis by PEN shows that in FY2005, the U.S. government spent only about one percent of the overall $1.2 billion federal nanotechnology research investment on highly relevant risk research. For more information, see:

The current strategy suggests that things have improved, but according to Rejeski only 40% of the listed research projects are highly relevant to understanding potential nanotechnology risksthe remaining 60% have only tangential relevance. Transparency over what is being done and what needs to be done is essential to strategic planning. The cited $68 million invested in nanotechnology risk research in fiscal year 2006 is an inflated estimate of work that directly addresses the issues, and that can only further confound the formulation of an effective strategic plan.


Contact: Colin Finan
Project on Emerging Nanotechnologies

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
3. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
4. Zimmer Announces Settlement of Federal Investigation
5. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
6. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
7. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
8. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
9. NASA technology forms the basis for a new nanotechnology company
10. Superbugs, shapes and nanotechnology
11. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):